Inactive Instrument

News Atossa Genetics Inc Nasdaq

Equities

US04962H1005

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 15	Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	CI
Apr. 09	Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib in Women with ER+/HER2- Breast Cancer	Apr. 16	AQ
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer	Apr. 15	AQ
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer	Apr. 15	CI
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference	Apr. 11	AQ
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	Apr. 09	AQ
Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen	Apr. 09	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update	Apr. 01	AQ
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient	Mar. 20	AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient	Mar. 19	AQ
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient	Mar. 19	CI
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements	Mar. 18	AQ
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors	Mar. 12	AQ
Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors	Mar. 12	CI
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting	Mar. 06	AQ
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study	Feb. 22	AQ
Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	Feb. 22	CI
Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating	Feb. 12	MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4	Feb. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Atossa Genetics Inc Nasdaq

Equities

US04962H1005

Summary

Filters